Every 10-Q that United-Guardian, Inc. (UG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow UG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UG filings page.
United-Guardian, Inc. reported higher results for the three and six months ended June 30, 2026. Net sales were $3.11 million for the quarter and $5.98 million for the first half, increases of 10% and 12% versus 2025, driven mainly by cosmetic and sexual wellness ingredients and stronger pharmaceutical sales.
Quarterly net income was $728,579 and first-half net income was $1,547,481, with EPS of $0.16 for the quarter and $0.34 year-to-date. Gross margin pressure was evident as cost of sales rose to 50% of net sales for both the quarter and first half. Medical lubricant revenue declined, while customer and supplier concentration remains high, with a small group of distributors and raw material suppliers accounting for most sales and purchases.
Liquidity is strong: cash and cash equivalents rose to $2.39 million, total marketable securities were $7.20 million, and total assets reached $13.59 million with no debt. Working capital increased to $10.98 million and the company continued returning capital through cash dividends, though the first-half dividend rate was reduced.
United-Guardian, Inc. reported stronger first‑quarter 2026 results. Net sales rose to $2,872,222, up about 16% from 2025, driven mainly by higher pharmaceutical revenue, especially Renacidin and Clorpactin, and solid growth in Lubrajel cosmetic ingredients.
Net income increased to $818,902 from $560,895, with earnings per share improving to $0.18 from $0.12. A key contributor was $303,133 of settlement income from Renacidin’s contract manufacturer following a prior facility shutdown. Operating income grew more modestly as cost of sales rose to 50% of net sales versus 45% a year earlier.
The company generated $604,536 of cash from operations and ended March 31, 2026 with $735,854 in cash and cash equivalents and $7,300,389 in marketable securities. Working capital was $10,344,756 with a current ratio of 8.1 to 1. The board declared a quarterly dividend of $0.25 per share, down from $0.35 in the prior‑year quarter. Management highlights significant customer and supplier concentrations and ongoing exposure to global trade, tariff, and supply chain risks.
United-Guardian (UG) filed its Q3 2025 10-Q reporting lower sales and earnings. Net sales were $2,264,261, down from $3,060,113 a year ago, with nine‑month sales at $7,583,613 versus $9,705,262. Net income was $268,441 in the quarter (vs. $865,484) and $1,456,162 year‑to‑date (vs. $2,747,151). EPS was $0.06 for the quarter (vs. $0.19) and $0.32 year‑to‑date (vs. $0.60).
Mix and volume pressures weighed on margins: cost of sales rose to 58% of sales in Q3 (46% prior year) and to 50% for the nine months (47% prior year), reflecting a higher contribution from lower‑margin pharmaceuticals and lower cosmetic volumes. Cosmetic ingredient sales softened, particularly tied to China demand and tariff dynamics, while pharmaceuticals grew on both a gross and net basis.
Operating cash flow was $1,636,324 for the nine months. The company paid cash dividends of $0.35 per share in February and $0.25 per share in August. Management highlighted ongoing tariff uncertainty related to China and noted the Natrajel launch timing has shifted to 2026 due to customer timelines. Working capital remains strong with a 7.0:1 current ratio.
United-Guardian (UG) posted softer Q2 FY25 results amid tariff-related demand weakness in Asia. Net sales fell 16% YoY to $2.84 m, pulling H1 revenue down 20% to $5.32 m. Cosmetic ingredients—heavily exposed to China through key distributor ASI—dropped 37% in the quarter, while pharmaceuticals rose 3% and medical lubricants slid 12%.
Gross margin held near 53%, but a 15% rise in operating expenses cut operating profit 38% to $0.70 m. Net income declined 34% to $0.63 m (EPS $0.14); H1 earnings were 37% lower at $1.19 m (EPS $0.26).
Operating cash flow shrank to $0.63 m from $1.97 m. Cash, equivalents and marketable securities total $8.42 m, supporting a 6.7× current ratio and debt-free balance sheet. Retained earnings eased after a $0.35/share dividend paid in Feb; another $0.25/share dividend was declared 11 Jul 25 for payment on 1 Aug 25.
Management flags heightened risk from new U.S. tariffs effective Aug-25 and possible Chinese retaliation, given ~40% of ASI resale volume is China-bound. Customer (one distributor 75%+) and supplier concentration remain structural risks. The company expects its new Natrajel sexual-wellness line to begin contributing in H2 25, offering a prospective growth lever.